Loading...
Market
Largest market for Emblaveo by end of 2025
4
Resolution / Starting Odds
Europe • 33%
North America • 33%
Asia • 34%
Market research reports or Pfizer's regional sales data
Story
EU Approves Pfizer's Emblaveo for Gram-Negative Bacterial Infections
Apr 22, 2024, 12:41 PM
The European Commission has approved Pfizer's new antibiotic, Emblaveo (aztreonam-avibactam), for treating multidrug-resistant infections caused by Gram-negative bacteria, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). This approval, endorsed by the European Medicines Agency, addresses the critical need for treatments against severe infections with limited options.
View original story
Similar markets
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
Below 10% • 25%
10% - 25% • 25%
25% - 50% • 25%
Above 50% • 25%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
United States • 33%
European Union • 33%
Canada • 33%
GSK • 33%
Pfizer • 33%
Moderna • 34%